Read more
After the FDA PCAC Vote: What's Changed, and What Hasn't
Six weeks ago we published a detailed breakdown of what the July PCAC vote actually meant and, more importantly, what it didn't. The short version: six peptides received favorable advisory recommendations, nothing became legal to compound overnight, and a wave of "FDA-approved!" marketing began circulating
A Peptide for Low Sexual Desire in Men. What a New Brain-Imaging Study of Kisspeptin Found
Most peptides are in a gray zone. They're interesting, but have little human data, no regulatory approval. Every so often, though, a peptide shows up in a top-tier medical journal with a properly designed human trial behind it. Kisspeptin is one of those, and a study published
The FDA Peptide Vote: What Just Happened, and What It Actually Means
On July 23 and 24, 2026, at the FDA's White Oak campus, something happened that reporters in the room described as causing an audible gasp: an FDA advisory committee publicly overruled the agency's own scientists. Then it did it five more times. By the end of
Is Epitalon's Telomerase Activity a Concern?
Telomerase is not an unambiguously good thing to switch on. This same enzyme that could theoretically slow cellular aging is the enzyme that roughly 85–90% of cancers reactivate to become immortal.